Lipoprotein(a) and cardiovascular risk in stage 4 CKD patients not on dialysis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study observes patients with stage 4 chronic kidney disease who are not on renal replacement therapy to see if higher lipoprotein(a) levels correspond to cardiovascular comorbidity after accounting for other risk factors. Blood levels of Lp(a) are measured to explore their association with cardiovascular events such as heart attack or stroke. The analysis will adjust for factors like diabetes, obesity, smoking, LDL cholesterol, and ongoing cardiovascular prevention therapies. Follow-up extends to 18 months to assess the relationship between Lp(a) and cardiovascular outcomes. The study is conducted at a single center in Nîmes, led by CHU de Nîmes, with no additional listed collaborators.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The patient must have given their free and informed consent and signed the consent form
* The patient must be a member or beneficiary of a health insurance plan
* Patient being followed at the Nîmes University Hospital for stage 4 chronic kidney disease without replacement therapy
* Patient available for follow-up at 18 months

Exclusion Criteria:

* The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study
* The subject refuses to sign the consent
* It is impossible to give the subject informed information
* The patient is under safeguard of justice or state guardianship
* Familial hypercholesterolemia
* Morbid obesity (BMI \> 40 kg/m2).
* Persons deprived of their liberty by a judicial or administrative decision, persons receiving psychiatric care, and persons admitted to a health or social care facility for purposes other than research (Article L1121-6 of the French Public Health Code)

Where it's running

• CHU de Nîmes - Hôpital Universitaire Carémeau
  Nîmes, France Recruiting

Study contacts

• Principal investigator: Olivier Moranne — Centre Hospitalier Universitaire de Nīmes
• Study coordinator: Olivier Moranne
• Email: olivier.moranne@chu-nimes.fr
• Phone: 04.66.68.32.59

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Vicadrostat versus spironolactone: effects on kidney function and protein markers

  This will test whether vicadrostat or spironolactone, each given with empagliflozin, changes kidney function and blood/urine protein patterns in adults with CKD and heart disease or heart failure.

  Recruiting at 2 sites Phase 2 University Medical Center Groningen · Groningen, Provincie Groningen and 1 other locations · NCT07304817

• Abnormal menstrual bleeding in women on antithrombotic drugs after heart surgery

  This study looks at whether women on blood thinners after heart surgery have abnormal menstrual bleeding and what factors might put some at higher risk.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07870941

• AI-powered ECG to help diagnose and predict outcomes in heart disease

  Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07856472

• Colchicine for preventing cardiovascular disease in adults with type 2 diabetes

  A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.

  Recruiting Phase 2 Tan Tock Seng Hospital · Singapore, Singapore · NCT07837934

• Optimised Cardio-Renal Care for CKD and heart disease

  This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.

  Recruiting Odense University Hospital · Svendborg · NCT07835828

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.